CorMedix Therapeutics will present a corporate overview at the J.P. Morgan Healthcare Conference on January 12, 2026.
Quiver AI Summary
CorMedix Therapeutics, a biopharmaceutical company specializing in therapeutic products for critical diseases, announced that its Chairman and CEO, Joseph Todisco, will present a corporate overview at the upcoming 44th annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 pm PST. The company is focused on the commercialization of its product DefenCath, designed to prevent catheter-related bloodstream infections in hemodialysis patients, as well as a range of anti-infective products following its acquisition of Melinta Therapeutics. CorMedix is conducting clinical studies for DefenCath in various patient populations and has ongoing research for its product REZZAYO, which is currently approved for specific fungal infections. Topline results for REZZAYO's Phase III study are expected in Q2 2026. More information can be found on their websites.
Potential Positives
- CorMedix Therapeutics is presenting at the prestigious 44th annual J.P. Morgan Healthcare Conference, showcasing its commitment to transparency and engagement with the investment community.
- The company's ongoing clinical studies for DefenCath indicate a focus on expanding its product applications, potentially leading to increased market opportunities.
- CorMedix's acquisition of Melinta Therapeutics LLC enhances its product portfolio, providing access to a range of anti-infective products that could drive revenue growth.
- Topline results of the Phase III study for REZZAYO are expected in Q2 2026, presenting an opportunity for future product approval and market expansion.
Potential Negatives
- None
FAQ
When is CorMedix presenting at the J.P. Morgan Healthcare Conference?
CorMedix will present on January 12, 2026, at 4:30 PM PST.
Who is the presenter for CorMedix at the conference?
Joseph Todisco, the Chairman and CEO of CorMedix Therapeutics, will be the presenter.
What is the focus of CorMedix Therapeutics?
CorMedix is focused on developing therapeutic products for life-threatening diseases and conditions.
What products does CorMedix currently commercialize?
CorMedix commercializes DefenCath and a portfolio of anti-infective products acquired from Melinta Therapeutics.
What clinical studies is CorMedix engaged in?
CorMedix has ongoing studies for DefenCath in TPN and Pediatric Hemodialysis populations.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRMD Insider Trading Activity
$CRMD insiders have traded $CRMD stock on the open market 14 times in the past 6 months. Of those trades, 1 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $CRMD stock by insiders over the last 6 months:
- JANET DILLIONE has made 0 purchases and 4 sales selling 137,000 shares for an estimated $1,478,755.
- JOSEPH TODISCO (Chief Executive Officer) has made 0 purchases and 2 sales selling 80,000 shares for an estimated $1,010,000.
- ELIZABETH HURLBURT (Chief Operating Officer) has made 0 purchases and 2 sales selling 53,997 shares for an estimated $711,817.
- KAUFMAN BETH ZELNICK (Chief Legal Officer) has made 0 purchases and 2 sales selling 50,000 shares for an estimated $670,264.
- STEVEN W LEFKOWITZ sold 40,000 shares for an estimated $475,200
- ALAN W DUNTON has made 0 purchases and 2 sales selling 30,000 shares for an estimated $391,300.
- MYRON KAPLAN purchased 25,000 shares for an estimated $275,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRMD Revenue
$CRMD had revenues of $104.3M in Q3 2025. This is an increase of 810.22% from the same period in the prior year.
You can track CRMD financials on Quiver Quantitative's CRMD stock page.
$CRMD Hedge Fund Activity
We have seen 144 institutional investors add shares of $CRMD stock to their portfolio, and 59 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. added 3,323,833 shares (+inf%) to their portfolio in Q3 2025, for an estimated $38,656,177
- MARSHALL WACE, LLP added 893,518 shares (+34.6%) to their portfolio in Q3 2025, for an estimated $10,391,614
- UBS GROUP AG added 814,964 shares (+295.3%) to their portfolio in Q3 2025, for an estimated $9,478,031
- JUMP FINANCIAL, LLC added 774,083 shares (+inf%) to their portfolio in Q3 2025, for an estimated $9,002,585
- NUVEEN, LLC removed 772,997 shares (-52.6%) from their portfolio in Q3 2025, for an estimated $8,989,955
- GHISALLO CAPITAL MANAGEMENT LLC removed 750,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,722,500
- ANSON FUNDS MANAGEMENT LP removed 725,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,431,750
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRMD Analyst Ratings
Wall Street analysts have issued reports on $CRMD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 01/08/2026
- D. Boral Capital issued a "Buy" rating on 12/18/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/13/2025
- RBC Capital issued a "Outperform" rating on 10/21/2025
- JMP Securities issued a "Market Outperform" rating on 09/09/2025
To track analyst ratings and price targets for $CRMD, check out Quiver Quantitative's $CRMD forecast page.
$CRMD Price Targets
Multiple analysts have issued price targets for $CRMD recently. We have seen 5 analysts offer price targets for $CRMD in the last 6 months, with a median target of $18.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $14.0 on 01/08/2026
- Serge Belanger from Needham set a target price of $15.0 on 01/08/2026
- Brandon Folkes from HC Wainwright & Co. set a target price of $18.0 on 11/13/2025
- Leonid Timashev from RBC Capital set a target price of $22.0 on 10/21/2025
- Jason N. Butler from JMP Securities set a target price of $22.0 on 09/09/2025
Full Release
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44 th annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST.
44th Annual J.P. Morgan Healthcare Conference
| Date: | Monday, January 12, 2026 |
| Time: | 4:30pm PST |
| Format: | Presentation |
| Webcast: |
Link
|
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath ® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN ® (minocycline) for Injection, REZZAYO ® (rezafungin for injection), VABOMERE ® (meropenem and vaborbactam), ORBACTIV ™ (oritavancin), BAXDELA ® (delafloxacin), and KIMYRSA ® (oritavancin), as well as TOPROL-XL ® (metoprolol succinate).
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com .
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
[email protected]
(617) 430-7576
